Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash & Equivalents (2019 - 2025)

Eton Pharmaceuticals' Cash & Equivalents history spans 7 years, with the latest figure at $37.1 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents rose 83.21% year-over-year to $37.1 million; the TTM value through Sep 2025 reached $37.1 million, up 83.21%, while the annual FY2024 figure was $14.9 million, 30.17% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $37.1 million at Eton Pharmaceuticals, up from $25.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $37.1 million in Q3 2025 and bottomed at $13.4 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $17.7 million (2024), against an average of $20.0 million.
  • The largest annual shift saw Cash & Equivalents soared 209.72% in 2021 before it plummeted 41.09% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $14.4 million in 2021, then increased by 13.18% to $16.3 million in 2022, then soared by 31.17% to $21.4 million in 2023, then tumbled by 30.17% to $14.9 million in 2024, then surged by 148.53% to $37.1 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Cash & Equivalents are $37.1 million (Q3 2025), $25.4 million (Q2 2025), and $17.4 million (Q1 2025).